ImmunoGen Inc (IMGN.OQ)
IMGN.OQ on NASDAQ Stock Exchange Global Select Market
10.52USD
26 Apr 2018
10.52USD
26 Apr 2018
Change (% chg)
$0.16 (+1.54%)
$0.16 (+1.54%)
Prev Close
$10.36
$10.36
Open
$10.47
$10.47
Day's High
$10.67
$10.67
Day's Low
$10.26
$10.26
Volume
370,960
370,960
Avg. Vol
837,826
837,826
52-wk High
$13.41
$13.41
52-wk Low
$3.73
$3.73
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2017 | Dec '17 | 39.45 | -0.105 |
| Sep '17 | 8.48 | -0.609 | |
| Jun '17 | 39.02 | -0.102 | |
| Mar '17 | 28.50 | -0.199 | |
| FY 2016 | Dec '16 | 13.85 | -0.392 |
| Sep '16 | 7.66 | -0.514 | |
| Dec | 18.03 | -0.382 | |
| Sep | 14.85 | -0.389 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 9 | 16.40 | 24.44 | 14.00 | -- |
| Quarter Ending Sep-18 | 9 | 15.30 | 16.60 | 12.41 | -- |
| Year Ending Dec-18 | 10 | 63.10 | 67.64 | 61.00 | 62.99 |
| Year Ending Dec-19 | 10 | 81.80 | 181.74 | 48.02 | 93.22 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 9 | -0.27 | -0.23 | -0.30 | -- |
| Quarter Ending Sep-18 | 9 | -0.29 | -0.26 | -0.38 | -- |
| Year Ending Dec-18 | 10 | -1.09 | -1.02 | -1.22 | -1.38 |
| Year Ending Dec-19 | 10 | -0.95 | -0.25 | -1.22 | -1.03 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
Dividends
Growth Rates
Financial Strength
Profitability Ratios
Efficiency
Management Effectiveness
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -- | -- | -- |
| EPS (TTM) % | -- | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for ImmunoGen Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | -7.56 | -10.74 | 19 | -- |
| 13 Week | -11.38 | -15.70 | 31 | -- |
| 26 Week | 119.55 | 102.86 | 94 | -- |
| 52 Week | 165.50 | 125.04 | 93 | -- |
| YTD | 235.78 | 194.89 | 96 | -- |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Immunogen Completes Interim Analysis For Forward I Phase 3 Trial Of Mirvetuximab Soravtansine
- BRIEF-Immunogen Inc Files For Potential Mixed Shelf Offering
- BRIEF-Immunogen Inc Reports Qtrly Net Loss Per Common Share, Basic And Diluted Of $0.11
- BRIEF-Immunogen Says On Jan 8, Co Disclosed It Expects To Report That As Of Dec 31, 2017 It Had Cash And Cash Equivalents Of About $267.1 Mln
- BRIEF-ImmunoGen Announces First Patient Dosed In Phase 1 Study Of IMGN632 For Hematological Malignancies
Institutional Holders
| % Shares Owned: | 80.31% |
| # of Holders: | 265 |
| Total Shares Held: | 106,687,116 |
| 3 Mo. Net Change: | 359,575 |
| # New Positions: | 7 |
| # Closed Positions: | 5 |
| # Increased Positions: | 20 |
| # Reduced Positions: | 17 |
| # Net Buyers: | 3 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.